SAN FRANCISCO It was just a coincidence when Cooley’s Jennifer Fonner DiNucci sat next to Jazz Pharmaceuticals CEO Bruce Cozadd at a deal-closing dinner in 2004. But their conversation not only led to a long-term business relationship culminating in a $650 million acquisition this week, it also had a profound impact on her family.
DiNucci’s sister was ill, and she found out Jazz made a drug that could help her.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
